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Introduction
Polymorphisms in members of the GST supergene family
have been associated with individual susceptibility to lung
diseases [1]. In the context of asthma GSTP1 — the pre-
dominant GST expressed in human lung [2] — is a candi-
date because this enzyme has a role in cellular protection
against oxidative stress [3]. Thus, GSTP1 catalyzes the
detoxification of byproducts of lipid and DNA oxidation
[1]. Asthma is characterized by airway inflammation [4].
Indeed, BHR reflects the presence of inflammation, and is
exhibited by virtually all asthmatic patients. Atopic individ-
uals (as defined by serum IgE levels and skin prick tests)
Abstract
Background: The glutathione S-transferase (GST) enzyme GSTP1 utilizes byproducts of oxidative
stress. We previously showed that alleles of GSTP1 that encode the Ile105®Val105 substitution are
associated with the asthma phenotypes of atopy and bronchial hyperresponsiveness (BHR). However,
a further polymorphic site (Ala114®Val114) has been identified that results in the following alleles:
GSTP1*A (wild-type Ile105®Ala114),  GSTP1*B (Val105®Ala114),  GSTP1*C  (Val105®Val114)
and GSTP1*D (Ile105®Val114).
Methods: Because full identification of GSTP1 alleles may identify stronger links with asthma
phenotypes, we describe an amplification refractory mutation system (ARMS) assay that allows
identification of all genotypes. We explored whether the GSTP1 substitutions influence susceptibility
to asthma, atopy and BHR.
Results: Among 191 atopic nonasthmatic, atopic asthmatic and nonatopic nonasthmatic individuals,
none had the BD, CD, or DD genotypes. GSTP1 BC was significantly associated with reduced risk for
atopy (P = 0.031). Compared with AA, trend test analysis identified a significant decrease in the
frequency of GSTP1 BC with increasing severity of BHR (P = 0.031). Similarly, the frequency of
GSTP1 AA increased with increasing BHR.
Conclusion: These data suggest that GSTP1*B and possibly GSTP1*C are protective against asthma
and related phenotypes.
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are very likely to have increased airway responsiveness
[4]. Thus, studies designed to identify susceptibility
genes for asthma must consider the possible interrela-
tionship of BHR and atopy in the expression of the
asthma phenotype.
We previously showed that the Ile105®Val105 substitu-
tion in GSTP1 is strongly associated with severity of BHR
[5]. A further polymorphism is present at amino acid 114
(Ala114®Val114), however, indicating that unequivocal
identification of GSTP1 alleles requires consideration of
both substitutions. These polymorphisms give rise to
wild-type  GSTP1*A (Ile105®Ala114),  GSTP1*B
(Val105®Ala114),  GSTP1*C (Val105®Val114) and
GSTP1*D (Ile105®Val114) [6–9]. Although the Ile105
variant has a higher catalytic efficiency for 1-chloro-2,4-
dinitrobenzene than does the Val105 variant [6], the
Val105 variant appears to confer higher catalytic effi-
ciency for polycyclic aromatic hydrocarbon diol epoxides
[7–11]. The effect of the Ala114®Val114 substitution is
unclear, although it may enhance the effect of the
Ile105®Val105 substitution [11].
Because the substitution at amino acid 114 may modify
the association of GSTP1 Ile105®Val105 with asthma
phenotypes, we developed an ARMS assay in order to
identify unambiguously those genotypes that result from
the A, B, C and D alleles. This approach is necessary,
because presently described assays do not differentiate
AC and BD genotypes. We also determined the frequen-
cies of these genotypes in atopic nonasthmatic, atopic
asthmatic and nonatopic nonasthmatic healthy persons.
Materials and methods
Patients
Unrelated Northern European nonatopic nonasthmatic,
atopic nonasthmatic and atopic asthmatic persons (n =
191) were recruited in North Staffordshire, UK [5]. They
were stratified by degree of airway reactivity/obstruction
as follows (Table 1): group 1, BHR negative (normal), with
forced expiratory volume in 1 s (FEV1) greater than 80%
predicted and PC20 greater than 16 mg/ml metacholine;
group 2, borderline BHR (mild) with FEV1 greater than
80% predicted and PC20 positive with 8–16 mg/ml meta-
choline; group 3, BHR positive (moderate) with FEV1
greater than 80% predicted and provoking concentration
of an inhaled substance that causes a 20% reduction in
FEV1 (PC20) positive with 0.03–8 mg/ml metacholine; and
group 4, severe airway dysfunction, with FEV1 of 80% or
less than predicted, which was not challenged with meta-
choline for ethical reasons. A positive skin reaction (mean
wheal diameter of at least 3 mm more than with saline
control) in response to at least one of a panel of seven
common aeroallergens (house dust mite, house dust,
grass mix, tree pollen, cat fur, dog fur, feathers) and serum
IgE levels greater than 100 IU/ml were used to define
atopic status, together with personal history. The local
Ethics Committee approved the study, and all participants
provided written informed consent.
Determination of GSTP1 genotypes
Genotyping was performed using leucocyte DNA. The
Ile105®Val105 substitution was identified using primers
to exon 5 as previously described [7,12]. The
Ala114®Val114 substitution was identified as described
Table 1
Clinical parameters of recruited subjects
FEV1 >80% predicted*
BHR negative  BHR positive  BHR positive
(PC20 >16 mg/ml;  (PC20 8–16 mg/ml;  (PC20 0.03–8 mg/ml;  FEV1 £80% predicted* 
Parameters group 1) group 2) group 3) (group 4)†
n (%) 58 (33.9) 15 (8.8) 51 (29.8) 47 (27.5)
Mean age ± SD (years) 37.0 ± 11.9 29.3 ± 6.8 33.0 ± 11.1 41.4 ± 11.0
Males (n [%]) 18 (31.0) 4 (26.7) 13 (25.5) 16 (34.0)
Females (n [%]) 40 (69.0) 11 (73.3) 38 (74.5) 31 (66.0)
Skin test negative (n [%]) 32 (55.2) 7 (46.7) 12 (23.5) 7 (14.9)
Skin test positive (n [%]) 26 (44.8) 8 (53.3) 39 (79.5) 40 (85.1)
IgE £100 IU/ml* (n [%]) 38 (71.7) 10 (83.3) 21 (46.7) 16 (40.0)
IgE >100 IU/ml* (n [%]) 15 (28.3) 2 (16.9) 24 (53.3) 24 (60.0)
*In some patients we were unable to obtain a complete data set. Some individuals were unwilling to undertake a metacholine challenge test,
whereas others did not wish to donate a blood sample (in this case DNA was isolated from a mouthwash sample). †Mean FEV1 = 67% predicted
(min = 45%, max = 78%).c
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by Board et al [13], with an annealing temperature of
65°C. However, GSTP1 AC and BD gave heterozygous
patterns using both of the above assays. An ARMS assay
was therefore developed to differentiate between these
genotypes. This included a forward primer upstream of the
codon 105 substitution (5¢-ACCCCAGGGCTC-
TATGGGAA-3¢) and two reverse primers (primer A
[Ala114 specific], 5¢-TCACATAGTCATCCTTGCCGG-3¢;
and primer B [Val114 specific], 5¢-TCACATAGTCATC-
CTTGCCGA-3¢).
For each DNA sample two polymerase chain reactions
(PCRs) were performed, amplifying a 998 base pair frag-
ment. PCRs were carried out in 50 ml containing forward
primer, reverse primer A or B (2 × 0.25 mmol/l), Taq poly-
merase (1 U), dNTP (4 × 200 mmol/l), 1 × polymerase
buffer (10 mmol/l Tris-HCl pH 9.0, 50 mmol/l KCl, 0.1%
[vol/vol] Triton X-100, 1.5 mmol/l MgCl2), and target DNA
(approximately 0.5 mg). Conditions were as follows: 94°C
for 4 min, 30 cycles of denaturation (94°C, 1 min), primer
annealing (62°C, 1 min) and elongation (72°C, 2 min).
The initial ARMS PCR was used to determine the
Ala114®Val114 genotype. Thus, in persons with
Ala114/Ala114 amplification occurred only with primer A,
and only with primer B in persons with Val114/Val114; for
Ala114/Val114 heterozygotes, amplification occurred with
both primers. ARMS PCR products were then digested
with  Bsm AI to determine the cis/trans configuration
(which variant at position 105 is paired with which allele at
position 114) of the Ile105®Val105 encoding allele and
resolved in 2% (vol/weight) agarose gels. Products gave
fragments of 343, 322, 260 and 73 base pairs with
Ile105/Ile105; 93, 250, 322, 260 and 73 base pairs with
Val105/Val105; and all six fragments in heterozygotes
(Ile105/Val105; Fig. 1).
Every run (including both restriction fragment length poly-
morphism and ARMS assays) included DNA samples of
known genotype as positive controls and one negative
control (no DNA). Samples with AA (Ala114/Ala114) and
CC (Val114/Val114) were used to optimize the proce-
dure, and as controls for the ARMS PCR. As an assess-
ment of quality control, approximately 15% of DNA
samples were reassayed at least once in order to confirm
the assigned genotype. All results from the reassayed
samples were consistent with the original genotype
assignment.
Available online http://respiratory-research.com/content/2/4/255
Figure 1
Illustration of the sites of primers and Bsm AI restriction endonuclease maps of the variant GSTP1, together with the banding patterns obtained from
the ARMS assay for each genotype. Products gave fragments of 343, 322, 260 and 73 base pairs with Ile105/Ile105; 93, 250, 322, 260 and 73
base pairs with the Val105/Val105; and all six fragments in heterozygotes (Ile105/Val105). Base pair numbering according to Morrow et al [21].Statistical analysis
c2 tests were used to assess homogeneity between
groups (eg skin test positive versus skin test negative). As
some allele frequencies were small, the StatXact-Turbo
(version 3; Cytel Software Corporation, Cambridge, MA,
USA) statistical package was used when appropriate. All
other statistical analyses were performed using the Stata
statistical package (version 6; Stata Corporation, College
Station, TX, USA). In order to correct for imbalances in
age and sex between groups, logistic regression was
used. The Armitage trend test was used to examine the
relationship between genotypes and ordered categories
(eg degree of BHR). In order to correct these trend test
analyses for potential confounding factors such as age
and sex, ordered logistic regression models were applied.
Results
Determination of GSTP1 genotypes
Using the two PCR assays it was possible to identify all
genotypes unambiguously, except 24 heterozygotes for
the Ile105®Val105 and Ala114®Val114 substitutions,
which could have been GSTP1 AC or BD. Accordingly,
ARMS PCR was used to identify these genotypes.
Banding patterns are shown in Supplementary Figure 1.
The frequencies of GSTP1 genotypes are shown in
Table 2. In 191 persons, none had BD, CD or DD, reflect-
ing the rarity of GSTP1*D. The frequencies of GSTP1
genotypes achieved Hardy–Weinberg equilibrium. As
reported previously [14], we found significant
(P < 0.0001, c2
4 = 50.9) linkage disequilibrium between
Ile105 and Ala114 and between Val105 and Val114.
Association of GSTP1 genotype with atopic indices
Table 2 shows the association of GSTP1 genotypes with
skin test positivity or IgE level. The frequencies of GSTP1
BB and BC were reduced in individuals with at least one
positive skin test (2.5 and 1.7%, respectively) as com-
pared with individuals who were skin test negative (5.6
and 9.9%, respectively). Although the frequency of
GSTP1 BB was not significantly lower in the persons with
positive skin tests (odds ratio [OR] 0.44; P = 0.297) or
with IgE levels of 100 IU/ml or less, GSTP1 BC was sig-
nificantly associated with skin test negativity (OR 0.17;
P = 0.031; Table 2). There were no significant associa-
tions between GSTP1 genotypes and IgE level, although
all individuals with GSTP1*B had IgE levels of 100 IU/ml
or less.
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Table 2
The association of GSTP1 genotype with atopic status and degree of airway reactivity/obstruction
Total  Skin test  Skin test  IgE £ IgE >
Genotype group negative positive 100 IU/ml 100 IU/ml Group 1 Group 2 Group 3 Group 4
AA 79 (42.4) 29 (40.9) 50 (41.7) 42 (43.3) 27 (38.6) 17 (29.3) 4 (26.7) 21 (41.2) 23 (48.9)
AB 66 (34.6) 21 (29.6) 45 (37.5) 30 (30.9) 30 (42.9) 24 (41.4) 6 (40.0) 21 (41.2) 14 (29.8)
AC 26 (13.6) 10 (14.1) 16 (13.3) 11 (11.3) 11 (15.7) 7 (12.1) 3 (20.0) 6 (11.8) 7 (14.9)
AD 2 (1.1) 0 (0) 2 (1.7) 1 (1.0) 1 (1.4) 1 (1.7) 0 (0) 0 (0) 1 (2.1)
BB 7 (3.7) 4 (5.6) 3 (2.5) 5 (5.2) 0 (0) 3 (5.2) 1 (6.7) 1 (2.0) 1 (2.1)
BC 9 (4.7) 7 (9.9) 2 (1.7)* 7 (7.2) 0 (0) 5 (8.6) 1 (6.7) 1 (2.0) 1 (2.1)
BD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CC 2 (1.1) 0 (0) 2 (1.7) 1 (1.0) 1 (1.4) 1 (1.7) 0 (0) 1 (2.0) 0 (0)
CD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
DD 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Alleles
GSTP1*A 0.660 0.627 0.679 0.649 0.686 0.569 0.567 0.676 0.731
GSTP1*B 0.233 0.254 0.221 0.242 0.214 0.302 0.300 0.235 0.172
GSTP1*C 0.102 0.120 0.092 0.103 0.093 0.121 0.133 0.088 0.086
GSTP1*D 0.005 0 0.008 0.005 0.007 0.009 0 0 0.011
Atopic status was defined as positive skin test and IgE 100 IU/ml or less. Groups were defined as follows: group 1, percentage predicted
>80%/PC20 >16 mg/ml; group 2, percentage predicted >80%/PC20 8–16 mg/ml; group 3, percentage predicted >80%/PC20 0–8 mg/ml; and
group 4, percentage predicted £80%. Values are expressed as number (%) for the genotype frequencies, or as proportions for the allele
frequencies. *Logistic regression analysis for skin test: uncorrected GSTP1 BC versus GSTP1 AA, OR 0.17, 95% CI 0.03–0.85 (P = 0.031); and
corrected for age and sex, OR 0.18, 95% CI 0.04–0.96 (P = 0.045). Trend test analysis across groups 1–4: uncorrected GSTP1 BC versus
GSTP1AA, P = 0.031; and corrected for age and sex, P = 0.02.Association of GSTP1 genotypes with airway
obstruction/reactivity
Table 2 shows the frequencies of GSTP1 genotypes in
relation to degree of airflow obstruction and BHR. The
GSTP1 AA frequency increased with severity of airway
reactivity/obstruction, whereas BB and BC frequencies
displayed a reverse trend. Compared with GSTP1 AA,
trend test analysis across the four groups revealed a sig-
nificant decrease in frequency of GSTP1 BC (and GSTP1
BB, albeit not significant) with increasing airway reactiv-
ity/obstruction (P = 0.031), indicating a protective effect.
This effect remained significant after correction for age
and sex (P = 0.022) using ordered logistic regression
analysis.
Association of GSTP1 genotype with presence of
asthma
We further examined the association of GSTP1 genotypes
with the clinical presence of asthma, as defined using the
recognized cutoff of <8 mg/ml methacholine [15] on
bronchial challenge (groups 1 and 2 versus groups 3 and
4). The frequency of GSTP1 AA was increased in
groups 3 and 4 (44.9%) as compared with groups 1 and
2 (28.8%), whereas GSTP1 BB and BC frequencies were
lower in groups 3 and 4 (2.0 and 2.0%, respectively) than
in groups 1 and 2 (5.5 and 8.2%, respectively). Thus,
GSTP1 BC was associated with a sixfold reduction in
asthma risk compared with GSTP1 AA (OR 0.16, 95%
confidence interval [CI] 0.03–0.86; P = 0.032). This asso-
ciation remained significant after correction for age and
sex (OR 0.15, 95% CI 0.03–0.80; P = 0.027).
Discussion
We showed that the 105 substitution in GSTP1 is associ-
ated with atopy and BHR [5]. We have now extended
these observations by examining whether the 114 substi-
tution modulates this effect. We determined the GSTP1
genotype using two reported PCR assays for each poly-
morphic site. However, these assays do not differentiate
GSTP1 AC and BD. Accordingly, we developed an ARMS
assay to allow identification of all genotypes.
GSTP1 is of particular interest in asthma, because chro-
mosome 11q13 is associated with its clinical phenotypes:
atopy and BHR [16]. Several candidates (high affinity IgE
receptor, clara cell secretory protein) have been identified,
although the encoding genes do not account for the
strength of the linkage to this region [16]. We proposed
that GSTP1 is another candidate gene in this region [17],
although it is of course possible that another gene may be
the target, and that the observed associations with
GSTP1 genotype reflect linkage disequilibrium with this
gene. Thus, the efficiency of detoxification of reactive
oxygen species products determined by polymorphism in
GSTP1 may influence the development and/or severity of
BHR and asthma.
We found that the frequency of GSTP1 AA was increased
in patients with established asthma. Similar findings have
been found in other proinflammatory conditions, such as
chronic obstructive pulmonary disease [18] and multiple
sclerosis [19]. However, studies in rheumatoid arthritis
[20] and basal cell carcinoma [12] show that GSTP1
Ile105/Ile105 is protective, whereas Val105/Val105 is
associated with a worse outcome. Thus, GSTP1-associ-
ated risk is likely to be disease-dependent, possibly
reflecting differences in relevant substrates.
The data reported here also show that the frequencies of
GSTP1 BC and BB were reduced in asthmatic persons,
thus indicating a protective effect. This supports the view
that there is little additional effect on disease risk from the
Ala114®Val114 substitution, although the number of indi-
viduals with some genotypes was small and larger
numbers would be required to confirm this observation.
The advantage with using this ARMS assay is that it is
possible to discriminate between genotypes AC and BD.
It relies on a relatively large fragment (998 base pairs),
however, and is therefore not suitable for genotyping of
archival DNA. Thus, this technique is applicable for
studies into population genetics.
In conclusion, we described an ARMS assay to identify
genotypes resulting from the A, B, C and D alleles of
GSTP1, and provided data on the effect of GSTP1 geno-
type on asthma risk. Our findings suggest that GSTP1*B
and GSTP1*C confer similar protective effects. However,
large patient groups are required to identify differential
effects between GSTP1*B, GSTP1*C and GSTP1*D.
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Supplementary Figure 1
Lanes 1, 3, 5, 7 and 9 include the amplified product from Ala114
specific primer, whereas lanes 2, 4, 6, 8 and 10 include the product
from the Val114 specific primer. PCR products from either primer give,
after digestion with Bsm AI, fragments of either 343, 322, 260 and 73
base pairs for the Ile105 allele, or 322, 260, 250, 93 and 73 base
pairs for the Val105 allele. Lane 11, molecular weight markers, pBR
Hae III. PCR products were visualized in 2% agarose gels.